GHK-Cu (Copper Tripeptide): Research Overview, Study Status, and Quality Criteria

GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine (sequence Gly-His-Lys), which carries a bound copper(II) ion. It was described in 1973 by Loren Pickart as a factor found in human serum. In scientific contexts, GHK-Cu is considered a subject of research for copper binding and gene expression. Within the context of EONA, GHK-Cu is exclusively research material: not an approved drug, not a cosmetic, and not intended for human or animal use. This overview explains what the peptide is, what preclinical research has been conducted on it, and what quality criteria apply to research material.

Key Takeaways

• GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), amino acid sequence Gly-His-Lys. This class of metal-bound short peptides is referred to as copper peptides.
• The free peptide GHK was described in 1973 by Loren Pickart as a factor from human serum; copper binding is a central chemical characteristic.
• Available research is predominantly preclinical, meaning in vitro and animal models, and has investigated, among other things, copper binding and gene expression.
• As a copper complex, GHK-Cu places special demands on analytics (HPLC plus mass spectrometry, copper content in the COA).
• GHK-Cu is research material: not an approved drug, not a cosmetic product, not for human or animal use.

What is GHK-Cu?

GHK-Cu refers to a complex of two components: the tripeptide GHK and a bound copper(II) ion. The tripeptide consists of the three amino acids glycine, L-histidine, and L-lysine, linked in this order (sequence Gly-His-Lys). The full chemical name is glycyl-L-histidyl-L-lysine. In the notation GHK-Cu, the abbreviation GHK stands for the peptide and Cu for the bound copper. Because the molecule carries a metal ion, it is classified as a copper peptide.

GHK was first described in 1973 by Loren Pickart, who isolated and characterized a factor from human serum (Pickart and Thaler 1973). The histidine in the sequence is chemically significant for coordinating the copper ion: the peptide binds the metal via the imidazole nitrogen of histidine and other donor atoms, forming a defined copper complex. This copper binding distinguishes GHK-Cu structurally from the free, metal-free peptide GHK.

Structural data for both forms, i.e., the free tripeptide and the copper complex, are stored in public chemistry databases such as PubChem, including the empirical formula and molecular mass of the tripeptide. Such databases are the most reliable reference for the exact structure and identity of the substance. For a broader classification of what peptides are chemically and how they differ from proteins, the pillar article on what peptides are provides the foundation.

Within the scope of EONA, the classification is clear: GHK-Cu is research material. It is neither an approved drug nor a cosmetic or dietary supplement. The substance is not intended for human or animal use.

What has been researched about GHK-Cu?

The scientific literature on GHK and GHK-Cu dates back to the 1970s and is predominantly preclinical, meaning it is based on cell cultures (in vitro) and animal models. A summary overview can be found in Pickart and Margolina (2018) in the International Journal of Molecular Sciences. Important for classification: A significant portion of the GHK and GHK-Cu literature can be traced back to Loren Pickart himself, who was involved in both the initial description in 1973 and the review in 2018. Broad, independent replication is therefore limited, which must be considered when evaluating the data. The following points describe research subjects, not proven effects in humans.

A central topic was copper binding. Here, it was investigated how the tripeptide coordinates copper ions, how stable the resulting complex is, and how copper is distributed among different binding partners (Pickart and Margolina 2018). These questions are fundamentally chemical and biochemical and concern the properties of the substance itself. The structural chemistry of the complex, including its empirical formula and molecular mass, is also documented in public databases such as PubChem.

Another field concerned gene expression. In cell culture models, it was analyzed which genes were transcribed differently in the presence of GHK or GHK-Cu (Pickart and Margolina 2018). Such studies typically employ methods such as transcriptome analysis, and GHK-Cu is classified as a molecule whose influence on gene activity was observed in the model. No benefit or effect for humans can be derived from this.

Furthermore, tissue regeneration in preclinical models was a subject of investigation. In animal models and cell systems, GHK-Cu was studied in connection with regenerative processes, for example, regarding the response of tissues in standardized experimental setups (Pickart and Margolina 2018). These are also laboratory observations, not statements about human application.

When classifying the data, caution is advised. The findings primarily come from animal and in vitro models, some are older, a large portion of the literature stems from a single research lineage, and their transferability to humans has not been proven. GHK-Cu is not an approved drug, and the mentioned research topics do not imply any therapeutic or other efficacy claims. For those who wish to contextualize GHK-Cu with other researched peptides, the research overview on BPC-157 offers another example of a neutral presentation of a predominantly preclinical study landscape.

What purity and quality criteria apply to GHK-Cu?

For research material, analytical characterization is crucial, because only documented identity and purity make results reproducible. With GHK-Cu, there is an additional peculiarity: it is not a simple peptide, but a metal complex. This places additional demands on testing.

The central method for determining peptide purity is High-Performance Liquid Chromatography (HPLC). It separates the main substance from impurities and allows for a statement about the percentage of the target peptide. Mass spectrometry (MS) is used to confirm identity, i.e., the correct molecular mass. The combination of both methods is industry standard. How HPLC works and what a purity value signifies is extensively described in the guide on peptide purity and HPLC.

Proof is provided through a Certificate of Analysis (COA). A COA documents, among other things, the methods used, the determined purity, mass confirmation, and batch assignment. The guide on how to read a peptide COA explains in detail what to look for in such a document.

The following table summarizes the most important testing aspects.

Criterion	Method or Proof	What it shows
Peptide purity	HPLC	Percentage of target peptide, separation from impurities
Identity / Molecular mass	Mass Spectrometry (MS)	Confirmation that the correct substance is present
Copper content (special feature)	COA specification, complex characterization	Confirmation of bound copper in the complex
Batch reference	COA with batch number	Assignment of the test report to the specific batch
Independent testing	Third-party laboratory analysis	External counter-check of manufacturer's specifications

The specificity of the copper complex lies in the fact that pure peptide analysis is not sufficient for complete characterization. In addition to the identity and purity of the peptide component, the copper content is relevant as it defines the complex. A complete picture therefore results from the combination of peptide analytics and the documentation of the copper content in the COA.

What should you look for when sourcing GHK-Cu as research material?

When sourcing research material, traceability is key. A reputable supplier provides batch-specific certificates of analysis, transparently names the testing methods, and makes no claims of efficacy. Missing or generic COAs, untraceable batches, or health-related statements are red flags. A detailed checklist on how to recognize quality can be found in the guide on how to identify reputable peptide suppliers.

An additional sign of trustworthiness is external counter-verification. When a manufacturer's claims are confirmed by an independent laboratory analysis from a third-party lab, it increases the reliability of the documented values. Specialized analytical labs like Janoshik are often cited in the industry as examples of such third-party testing. The article on third-party lab testing for peptides describes how a third-party lab analysis works and how it should be interpreted.

Regarding origin, it's worth looking at verifiable factors rather than blanket country judgments. Relevant factors include regulatory frameworks, supply chain transparency, and access to independent testing. These points can be assessed concretely, unlike general claims of origin. A factual comparison of these factors can be found in the article Peptides from Europe compared to China.

Proper storage is also part of the traceability of research material, as peptides can be sensitive to temperature, light, and humidity. Information on this is summarized in the article on storing peptides.

EONA sees itself as a European research peptide brand with the aspiration to prove quality rather than just claim it. In line with this, the following remains true for GHK-Cu: It is research material, not a drug or cosmetic, and not intended for human or animal use.

Frequently Asked Questions about GHK-Cu

What is GHK-Cu?

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (sequence Gly-His-Lys). The peptide binds a copper ion, which chemically defines the complex. The free peptide was described in 1973 by Loren Pickart as a factor from human serum. In the EONA context, GHK-Cu is exclusively research material.

Is GHK-Cu a cosmetic product or an anti-aging agent?

No. Within the scope of EONA, GHK-Cu is research material and not a cosmetic, drug, or dietary supplement. No claims are made regarding skin, anti-aging, or any other effects. The substance is not intended for human or animal use.

What has been scientifically investigated about GHK-Cu?

Predominantly preclinical research, i.e., in vitro and animal models, has investigated, among other things, the peptide's copper binding, as well as its influence on gene expression and tissue regeneration in model systems. These works describe research subjects in the laboratory and do not prove any benefit or effect in humans.

How does GHK-Cu differ from other peptides in terms of analysis?

GHK-Cu is a metal complex, not a pure peptide. In addition to the usual peptide analytics with HPLC for purity and mass spectrometry for identity, the bound copper content is therefore relevant. A complete picture emerges from the combination of both aspects, documented in the Certificate of Analysis.

How do I recognize good research material?

Crucial factors include batch-specific certificates of analysis, transparently named testing methods (HPLC, MS), traceable batch assignments, and ideally, independent counter-verification by a third-party laboratory. Health-related efficacy claims, on the other hand, are a red flag.

Is GHK-Cu an approved drug?

No. GHK-Cu is not an approved drug. It is research material not intended for human or animal use.

Sources

1. Pickart, L., Margolina, A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987. (Review on GHK-Cu)
2. Pickart, L., Thaler, M. M. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology, 243, 85-87. (First description of the GHK factor)
3. PubChem, National Center for Biotechnology Information (NCBI). Entry for Glycyl-L-Histidyl-L-Lysine (structural data, empirical formula, molecular mass).

Related Articles

• What are Peptides? Basic Overview (Pillar)
• Understanding Peptide Purity and HPLC
• How to Read a Peptide COA Correctly
• Recognizing Reputable Peptide Suppliers
• Third-Party Lab Testing for Peptides
• Proper Peptide Storage
• Research Overview on BPC-157

Editorial Note

This article is for research purposes only and serves exclusively to provide neutral, fact-based information about GHK-Cu as research material. It does not constitute advice and contains no claims of efficacy, healing, or application. The referenced research is predominantly preclinical (in vitro and animal models), and the data's transferability to humans is limited. It should also be noted that a large part of the GHK and GHK-Cu literature originates from Loren Pickart himself (initial description in 1973 and review in 2018), which limits broad independent replication. GHK-Cu is not an approved drug, not a cosmetic, and not intended for human or animal use. Created by the EONA editorial team. Last updated: June 2026.